Boothbay Fund Management, LLC Tg Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $92,282 - $241,637	-11,816 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $9,834 - $22,974	647 Added 5.79%	11,816 $225,000
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $8,733 - $16,220	401 Added 3.72%	11,169 $372,000
Q2 2021 Aug 16, 2021	BUY	$32.5 - $48.96 $212,842 - $320,639	6,549 Added 155.23%	10,768 $418,000
Q1 2021 May 17, 2021	BUY	$41.61 - $54.3 $175,552 - $229,091	4,219 New	4,219 $203,000
Q1 2020 May 15, 2020	SELL	$7.14 - $15.99 $374,321 - $838,291	-52,426 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $267,372 - $587,171	52,426 New	52,426 $582,000
Q3 2019 Nov 14, 2019	SELL	$5.38 - $8.99 $322,444 - $538,806	-59,934 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.27 - $8.65 $375,786 - $518,429	59,934 New	59,934 $518,000
Q1 2019 May 15, 2019	SELL	$4.02 - $8.04 $87,523 - $175,046	-21,772 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $62,239 - $104,215	-18,093 Reduced 45.39%	21,772 $89,000
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $205,304 - $558,110	39,865 New	39,865 $223,000

336

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.